Dec 19, 2009 0
Revlimid Meets Primary Endpoint In A Phase III Study
The initial data from a Phase III study using the Revlimid in multiple myeloma patients who had undergone stem cell transplant reported that the trial had met its primary endpoint of a statistically significant improvement in time to disease progression. Read the rest of this entry »
Most Commented